The U.K. NorthStar Clinical Network

Not yet recruiting

• Conditions: Duchenne Muscular Dystrophy

• Registration Number: NCT06711692
• Lead Sponsor: University College, London

Brief Summary

The goal of this natural history study is to capture the natural history of Duchenne Muscular Dystrophy (DMD) in children and adults in the United Kingdom. Children and adults with DMD will be invited to join.

The primary objective of the study is to collect longitudinal data on motor and respiratory function in DMD patients from childhood to adulthood.

The secondary objectives of the study include collection of longitudinal data on other aspects of natural history on DMD, including respiratory, cardiac and endocrine complications, neurodiversity (cognitive impairment, neuro-behavioural disorders such as ADHD and autism), changes to bone density and occurrence of fractures, changes to puberty, incidence of scoliosis, unplanned hospital admissions, and quality of life. The study will also collect information on ethnicity.

Participants will attend an annual or bi-annual neuromuscular clinic, and will have a series of assessments and questionnaires with the study team. These include: key medical data, physiotherapy data, respiratory assessments, Quality of Life questionnaires, and DMD questionnaires. Following assessments and questionnaire completion, data is input into the study's tailor-made National Neuromuscular Database.

Detailed Description

This study will make use of the existing NorthStar network to collect a wider range of clinically relevant data from paediatric and adult DMD patients, to describe more completely the natural history of the disease in different domains and across different life stages and disease phases. Data will be collected using assessment techniques and outcome measures appropriate to the major phases of the disease, and which are in some cases not currently part of the standard of care for DMD in the UK. The National Neuromuscular Database will continue to be used to collect and store these data. This study will allow the network to continue to describe the current natural history in DMD prospectively, with more robust subject ascertainment and completeness. This will help meet the current need for contemporary natural history data for the evaluation of new therapies, and further research in DMD.

Study Timeline

• Status Verified: 2024-11
• Study First Submitted: 2024-11-08
• Study First Submitted QC: 2024-11-26
• Last Update Submitted: 2024-11-26
• Study Start: 2024-12-01
• Study First Posted: 2024-12-02
• Last Update Posted: 2024-12-02
• Primary Completion: 2025-04-30
• Study Completion: 2025-06-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Male
• Target Recruitment: 300

Inclusion Criteria

• All patients with genetically confirmed diagnosis of Duchenne Muscular Dystrophy in the United Kingdom. Recruitment will also be possible in cases in whom the DMD diagnosis is made after a muscle biopsy even if the dystrophin gene variant is still being investigated.

Exclusion Criteria

• Involvement in clinical trials is not an exclusion criterion nor having had surgical procedures, as this is an observational research study. The regular clinical data of patients in clinical trials will be acquired as part of the clinical follow up.
• Patients based outside of the United Kingdom.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Longitudinal data on motor function in Duchenne Muscular Dystrophy (DMD) patients from the childhood to the adult phases of life	From enrolment to the end of the study, across 18 months	Measure: NorthStar Ambulatory Assessment (NSAA). a scale from 0 (unable), 1 (completes independently but with modifications), and 2 (completed without compensation). Total score 0 - 34 with a higher score denoting a higher level of function.

Secondary Outcome Measures

Name	Time	Method
Longitudinal data on quality of life in childhood and adult patients.	From enrolment to the end of the study, across 18 months	Measure: The Quality of Life in Genetic Neuromuscular Disease Questionnaire (QoL-gNMD). The QoL-gNMD domain is measured on a T score metric i.e. a normal distribution with a mean of 50 and a standard deviation of 10.; High values represent good quality of life.

Trial Locations

Locations (25)

Aberdeen, NHS Grampian; 🇬🇧 Aberdeen, United Kingdom

Belfast Health and Social Care Trust; 🇬🇧 Belfast, United Kingdom

Birmingham Children's Hospital; 🇬🇧 Birmingham, United Kingdom

Birmingham Community Healthcare NHS Foundation Trust; 🇬🇧 Birmingham, United Kingdom

Birmingham Heartlands Hospital; 🇬🇧 Birmingham, United Kingdom

University Hospitals Bristol and Weston; 🇬🇧 Bristol, United Kingdom

Cambridge University Hospitals; 🇬🇧 Cambridge, United Kingdom

Cardiff and Vale University Health Board; 🇬🇧 Cardiff, United Kingdom

NHS Dundee - Tayside; 🇬🇧 Dundee, United Kingdom

NHS Greater Glasgow and Clyde; 🇬🇧 Glasgow, United Kingdom

Scroll for more (15 remaining)